About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Twist Bioscience Corporation - Common Stock (NQ:TWST)

72.14 +2.10 (+3.00%)
Streaming Delayed Price Updated: 9:58 AM EDT, Jun 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Twist Bioscience Corporation - Common Stock

< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Gainers Protagenic Therapeutics (NASDAQ:PTIX) shares increased by 84.03% to $3.92 during Monday's regular session. Trading volume for this security as of 12:30 EST is... 
Via Benzinga
News headline image
Barron's Picks And Pans: Hannon Armstrong, Seagate, Tesla, Virtu Financial And More ↗
This weekend's Barron's cover story helps investors to prepare for the changes ahead. Other featured articles discuss how to invest in tomorrow's big tech trends,... 
Via Benzinga
News headline image
What Are the Risks With Twist Bioscience? ↗
One especially stands out. 
Via The Motley Fool
News headline image
Twist Bioscience Corp (TWST) Q2 2021 Earnings Call Transcript ↗
TWST earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Twist Bioscience Reports Second Quarter Fiscal 2021 Financial Results
From Twist Bioscience Corporation
Via Business Wire
News headline image
Earnings Scheduled For May 6, 2021 ↗
Companies Reporting Before The Bell • ViacomCBS (NASDAQ:VIAC) is projected to report quarterly earnings at $1.22 per share on revenue of $7.30 billion. • Cohen... 
Via Benzinga
News headline image
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge ↗
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
News headline image
Why Does Cathie Wood Like This Healthcare Stock So Much? ↗
Twist Bioscience brings to mind another genomic revolution pioneer. 
Via The Motley Fool
News headline image
3 Exciting Biotech Stocks to Buy Right Now ↗
Gene therapies could be poised to enter an era of extraordinarily rapid advancement. 
Via The Motley Fool
News headline image
Twist Bioscience and Vivlion Partner to Generate gRNA Libraries for CRISPR Applications
From Twist Bioscience Corporation
Via Business Wire
News headline image
Twist Bioscience to Report Fiscal 2021 Second Quarter Financial Results on Thursday, May 6, 2021
From Twist Bioscience Corporation
Via Business Wire
News headline image
Twist Bioscience to Expand Oregon Lease, Supporting Future Growth
From Twist Bioscience Corporation
Via Business Wire
News headline image
Pure Biologics Selects Twist Bioscience to Expand Phage Display Technology Capabilities
From Twist Bioscience Corporation
Via Business Wire
News headline image
Twist Bioscience Exercises Option to Purchase Custom Designed Antibody Library and Optimization Software
From Twist Bioscience
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 12, 2021 ↗
Upgrades For Eni SpA (NYSE:E), Credit Suisse upgraded the previous rating of Underperform to Neutral. For the fourth quarter, Eni had an EPS of $0.02, compared to year-ago... 
Via Benzinga
News headline image
Ginkgo Bioworks, Which Prints DNA And Creates Genetically Modified Food, Exploring SPAC Deal: Report ↗
One of the largest SPACs seeking a target could be nearing a $20 billion deal to bring one of the largest privately-held biotechnology companies public. The SPAC Rumor: Bloomberg... 
Via Benzinga
News headline image
AcornMed Selects Twist Bioscience Technology to Power Next Generation Precision Medicine Tests
From Twist Bioscience Corporation
Via Business Wire
News headline image
Twist Bioscience to Provide Antibody Discovery, Optimization and Access to Library of Libraries for Drug Research to Stanford University Laboratories
From Twist Bioscience Corporation
Via Business Wire
< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.